Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Cost Saving: The trade-off that bites back

Posted on April 3rd, 2017 by in Pharma R&D

Making a trade-off between competing activities or priorities is a critical skill involved in developing a new medicine. This approach helps balance the risk of technical failure and investment to develop innovative products, an important consideration with such high failure rates in pharma R&D. Continue reading “Cost Saving: The trade-off that bites back” »

Start-Up Spotlight: CuroNZ Ltd

Posted on March 3rd, 2017 by in Pharma R&D

In Auckland, New Zealand, one biotech start-up has set its sights on research that can advance the treatment of diseases of the central nervous system. That company is CuroNZ, and Chief Scientist and Managing Director Dr. Frank Sieg describes their excellent progress so far, and what’s ahead. Continue reading “Start-Up Spotlight: CuroNZ Ltd” »

Immune Checkpoints: New Promises in Cancer Treatment

Posted on October 26th, 2016 by in Pharma R&D

Cancer immunotherapy (especially checkpoint inhibitors) is hot in the cancer therapeutics world, but we are still learning about how best to use them and in which patients. The current explosion in new cancer immunotherapies relates to braking T-cell activation: checkpoint therapies. Continue reading “Immune Checkpoints: New Promises in Cancer Treatment” »

Crisis Prevention in Pharmacovigilance

Posted on October 12th, 2016 by in Pharmacovigilance

One of the challenging situations that Pharmacovigilance functions will have to manage one day or another is a pharmacovigilance crisis. Continue reading “Crisis Prevention in Pharmacovigilance” »

  1. 1
  2. 2
  3. 3